PolyNovo welcomes Bruce Peatey as CEO
Charlie Blackie-Kelly | October 22, 2025 | Appointment | | CEO, Market Expansion, PolyNovo, medtech, wound care
PolyNovo, an Australian medtech company specialising in acute complex wound management, has appointed Bruce Peatey as its new chief executive officer.
Peatey’s appointment is effective from the start of December 2025, and he will be succeeding Dr Robyn Elliott, who had been serving as interim CEO. According to the company, Peatey will spearhead PolyNovo’s expansion into new markets.
“Bruce has an authentic, approachable and driven manner – qualities that reflect his Australian roots and leadership style. He brings extensive experience in navigating distribution strategies, having worked with both direct sales models and third-party distributors at Dentsply Sirona and other organisations. This expertise will be instrumental as PolyNovo expands into the outpatient market and broadens its international presence,” commented PloyNovo chairman David Williams.
Prior to joining PolyNovo, Peatey was group vice president for the Americas at Dentsply Sirona, a dental equipment and consumables manufacturer. He held the same position for the Asia-Pacific (APAC) region between November 2022 and June 2024, and served on the company’s NASDAQ board.
He has also held senior leadership roles at Abbott Laboratories, Baxter Healthcare and Biosensors International, and has experience in strategic business development, market expansion, new product launches, and regulatory compliance.
Bruce Peatey, incoming CEO, said: “I’m honoured to join PolyNovo as chief executive officer at a pivotal moment in the company’s growth. PolyNovo exemplifies Australian innovation, delivering transformative solutions that improve patient outcomes globally. I’m excited to lead the next phase of expansion – into new markets, broader clinical applications and deeper partnerships – while continuing to build on the company’s strong foundation.”
Charlie Blackie-Kelly
Related Content
CMS commences formal review for Topical Oxygen Therapy coverage
11 November 2024 AOTI, INC. (AIM: AOTI), a medical technology group focussed on the durable …
SolasCure partners with US Army for better wound care technology
SolasCure, a biotechnology company which is dedicated to working towards filling the current market gap …
CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …
